Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02445781 · ClinicalTrials.gov registry record · Early Phase 1

Differing Levels of Hypoglycemia

A Early Phase 1 study of Hypoglycemia, sponsored by University of Maryland, Baltimore.

Recruiting
Registry status
Early Phase 1
Development phase
32
Enrollment target
2
Study locations

NCT02445781 is a Early Phase 1 study of Hypoglycemia that is actively recruiting participants, run by University of Maryland, Baltimore. The registered enrollment target is 32 participants, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02445781, a Early Phase 1 study of Hypoglycemia, is actively recruiting participants, sponsored by University of Maryland, Baltimore.

RECRUITING
Registry status
Early Phase 1
Development phase
32 participants
Enrollment target
2
Study locations

Study Summary

Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our study will be to determine the effects of differing levels of hypoglycemia on in-vivo vascular biologic mechanisms in a healthy population.

Conditions Studied

Interventions

  • DEVICE Glucose clamp

Study Locations (2)

Maryland

  • University of Maryland, Baltimore - Baltimore
  • University of Maryland, Baltimore - Baltimore

Trial Details

FieldValue
Enrollment Target 32 participants
Start Date 2015-07
Est. Completion 2026-12
Phase Early Phase 1

Sponsor

University of Maryland, Baltimore

560 total trials

What the Registry Record Tells You About NCT02445781

The ClinicalTrials.gov registry entry for NCT02445781 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 506-participant average among 40 other Hypoglycemia trials with a reported enrollment target (94% lower). The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypoglycemia appearing as the primary indexed condition, and to 1 intervention - of which Glucose clamp is the first listed.

NCT02445781 reports 2 study locations spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT02445781 about?

NCT02445781 is a clinical study titled "Differing Levels of Hypoglycemia". Hypoglycemia can produce a spectrum of pro-inflammatory and pro-atherothrombotic changes. To date no studies appear to have investigated the effects of differing levels of hypoglycemia on the vasculature and pro-atherothrombotic balance during hypoglycemia in healthy man. The specific aim of our stu...

What is the current status of trial NCT02445781?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 32 participants. The study started on 2015-07. Estimated completion is 2026-12.

What conditions does trial NCT02445781 study?

This clinical trial studies the following conditions: Hypoglycemia.

What interventions are being tested in trial NCT02445781?

The interventions under investigation include: Glucose clamp (DEVICE).

Who is sponsoring clinical trial NCT02445781?

This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02445781 being conducted?

This trial has 2 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoglycemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.